CYP2D6 genotype predicts tamoxifen discontinuation and drug response : a secondary analysis of the KARISMA trial
Citation
He , W , Eriksson , M , Eliasson , E , Grassmann , F , Bäcklund , M , Gabrielson , M , Hammarström , M , Margolin , S , Thorén , L , Wengström , Y , Borgquist , S , Hall , P & Czene , K 2021 , ' CYP2D6 genotype predicts tamoxifen discontinuation and drug response : a secondary analysis of the KARISMA trial ' , Annals of Oncology , vol. 32 , no. 10 , pp. 1286-1293 . https://doi.org/10.1016/j.annonc.2021.07.005
Rights
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).